Matthew G Oser
Overview
Explore the profile of Matthew G Oser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1054
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Baca S, Seo J, Davidsohn M, Fortunato B, Semaan K, Sotudian S, et al.
Nat Med
. 2023 Oct;
29(11):2737-2741.
PMID: 37865722
Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and...
12.
Duplaquet L, Li Y, Booker M, Xie Y, Olsen S, Patel R, et al.
Nat Cell Biol
. 2023 Aug;
25(9):1346-1358.
PMID: 37591951
Small cell lung cancer (SCLC) exists broadly in four molecular subtypes: ASCL1, NEUROD1, POU2F3 and Inflammatory. Initially, SCLC subtypes were thought to be mutually exclusive, but recent evidence shows intra-tumoural...
13.
Chen H, Durmaz Y, Li Y, Sabet A, Vajdi A, Denize T, et al.
Nat Commun
. 2022 Aug;
13(1):4998.
PMID: 36008402
Some small cell lung cancers (SCLCs) are highly sensitive to inhibitors of the histone demethylase LSD1. LSD1 inhibitors are thought to induce their anti-proliferative effects by blocking neuroendocrine differentiation, but...
14.
Hong D, Knelson E, Li Y, Durmaz Y, Gao W, Walton E, et al.
Cancer Res
. 2021 Nov;
82(2):248-263.
PMID: 34810201
Neuroendocrine to nonneuroendocrine plasticity supports small cell lung cancer (SCLC) tumorigenesis and promotes immunogenicity. Approximately 20% to 25% of SCLCs harbor loss-of-function (LOF) mutations. Previous studies demonstrated that NOTCH functions...
15.
Mahadevan N, Knelson E, Wolff J, Vajdi A, Saigi M, Campisi M, et al.
Cancer Discov
. 2021 Mar;
11(8):1952-1969.
PMID: 33707236
Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity, which could influence its immunobiology. Here we...
16.
Koduri V, Duplaquet L, Lampson B, Wang A, Sabet A, Ishoey M, et al.
Sci Adv
. 2021 Feb;
7(6).
PMID: 33547076
Most intracellular proteins lack hydrophobic pockets suitable for altering their function with drug-like small molecules. Recent studies indicate that some undruggable proteins can be targeted by compounds that can degrade...
17.
Zhang H, Christensen C, Dries R, Oser M, Deng J, Diskin B, et al.
Cancer Cell
. 2019 Dec;
37(1):37-54.e9.
PMID: 31883968
Cyclin-dependent kinase 7 (CDK7) is a central regulator of the cell cycle and gene transcription. However, little is known about its impact on genomic instability and cancer immunity. Using a...
18.
Oser M, Sabet A, Gao W, Chakraborty A, Schinzel A, Jennings R, et al.
Genes Dev
. 2019 Nov;
33(23-24):1718-1738.
PMID: 31727771
More than 90% of small cell lung cancers (SCLCs) harbor loss-of-function mutations in the tumor suppressor gene The canonical function of the gene product, pRB, is to repress the E2F...
19.
Schade A, Oser M, Nicholson H, DeCaprio J
Oncogene
. 2019 Mar;
38(25):4962-4976.
PMID: 30833638
The retinoblastoma protein (RB) restricts cell cycle gene expression and entry into the cell cycle. The RB-related protein p130 forms the DREAM (DP, RB-like, E2F, and MuvB) complex and contributes...
20.
Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion
Harris I, Endress J, Coloff J, Selfors L, McBrayer S, Rosenbluth J, et al.
Cell Metab
. 2019 Feb;
29(5):1166-1181.e6.
PMID: 30799286
Cells are subjected to oxidative stress during the initiation and progression of tumors, and this imposes selective pressure for cancer cells to adapt mechanisms to tolerate these conditions. Here, we...